CANY
QTTB icon

Caxton Associates (New York)’s Q32 Bio QTTB Stock Holding History

Caxton Associates (New York)’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,769
Closed -$535K – 777
2022
Q1 		$535K Buy
9,769
+7,377
+308% +$458K 0.04% 233
2021
Q4 		$157K Buy
2,392
+1,663
+228% +$161K 0.02% 506
2021
Q3 		$103K Buy
+729
New +$92.9K 0.01% 427

Other funds holding QTTB

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Caxton Associates (New York)'s QTTB Position: Q2 2022 in Review

Caxton Associates (New York) sold out of Q32 Bio (QTTB) in Q2 2022, closing a stake of 9,769 shares — an estimated $535K sold.

Caxton Associates (New York) first reported a position in QTTB in Q3 2021 and held it in 3 quarters. The position peaked at $535K in Q1 2022. 87 funds tracked by Wall St. Rank hold QTTB as of Q2 2022.

  • Caxton Associates (New York) reported no remaining Q32 Bio position as of Q2 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 9,769 Q32 Bio shares in Q2 2022, an estimated $535K.
  • Caxton Associates (New York) first reported a position in Q32 Bio in Q3 2021 and held it in 3 quarters.
  • Caxton Associates (New York)'s Q32 Bio position peaked at $535K in Q1 2022.
  • 87 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.